Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) - Net Assets
Based on the latest financial reports, Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) has net assets worth Rs1.49 Billion INR (≈ $16.10 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs2.94 Billion ≈ $31.79 Million USD) and total liabilities (Rs1.45 Billion ≈ $15.70 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Aarey Drugs & Pharmaceuticals Limited to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs1.49 Billion |
| % of Total Assets | 50.63% |
| Annual Growth Rate | 19.15% |
| 5-Year Change | 40.08% |
| 10-Year Change | 277.36% |
| Growth Volatility | 34.36 |
Aarey Drugs & Pharmaceuticals Limited - Net Assets Trend (2009–2025)
This chart illustrates how Aarey Drugs & Pharmaceuticals Limited's net assets have evolved over time, based on quarterly financial data. Also explore AAREYDRUGS asset base for the complete picture of this company's asset base.
Annual Net Assets for Aarey Drugs & Pharmaceuticals Limited (2009–2025)
The table below shows the annual net assets of Aarey Drugs & Pharmaceuticals Limited from 2009 to 2025. For live valuation and market cap data, see AAREYDRUGS company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs1.38 Billion ≈ $14.98 Million |
+4.30% |
| 2024-03-31 | Rs1.33 Billion ≈ $14.36 Million |
+13.08% |
| 2023-03-31 | Rs1.17 Billion ≈ $12.70 Million |
+3.32% |
| 2022-03-31 | Rs1.14 Billion ≈ $12.29 Million |
+14.95% |
| 2021-03-31 | Rs988.60 Million ≈ $10.69 Million |
+7.05% |
| 2020-03-31 | Rs923.46 Million ≈ $9.99 Million |
+6.69% |
| 2019-03-31 | Rs865.53 Million ≈ $9.36 Million |
+7.86% |
| 2018-03-31 | Rs802.45 Million ≈ $8.68 Million |
+59.34% |
| 2017-03-31 | Rs503.60 Million ≈ $5.45 Million |
+37.23% |
| 2016-03-31 | Rs366.97 Million ≈ $3.97 Million |
+3.64% |
| 2015-03-31 | Rs354.09 Million ≈ $3.83 Million |
+2.57% |
| 2014-03-31 | Rs345.21 Million ≈ $3.73 Million |
+3.14% |
| 2013-03-31 | Rs334.70 Million ≈ $3.62 Million |
+2.01% |
| 2012-03-31 | Rs328.12 Million ≈ $3.55 Million |
+49.79% |
| 2011-03-31 | Rs219.05 Million ≈ $2.37 Million |
+137.89% |
| 2010-03-31 | Rs92.08 Million ≈ $995.81K |
+9.65% |
| 2009-03-31 | Rs83.97 Million ≈ $908.15K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Aarey Drugs & Pharmaceuticals Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1687.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs571.32 Million | 41.26% |
| Common Stock | Rs280.54 Million | 20.26% |
| Other Comprehensive Income | Rs24.65 Million | 1.78% |
| Other Components | Rs508.29 Million | 36.70% |
| Total Equity | Rs1.38 Billion | 100.00% |
Aarey Drugs & Pharmaceuticals Limited Competitors by Market Cap
The table below lists competitors of Aarey Drugs & Pharmaceuticals Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Timberwell Bhd
KLSE:7854
|
$27.95 Million |
|
Malmbergs Elektriska AB (publ)
ST:MEAB-B
|
$27.97 Million |
|
Tien Wah Press Holdings Bhd
KLSE:7374
|
$27.98 Million |
|
MegaMD Co. Ltd
KQ:133750
|
$28.00 Million |
|
Optrontec Inc
KQ:082210
|
$27.93 Million |
|
Nova Agritech Ltd.
NSE:NOVAAGRI
|
$27.92 Million |
|
Simat Technologies Public Company Limited
BK:SIMAT
|
$27.90 Million |
|
Halloren Schokoladenfabrik Aktiengesellschaft
HM:H2RB
|
$27.89 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aarey Drugs & Pharmaceuticals Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,327,733,738 to 1,384,805,000, a change of 57,071,262 (4.3%).
- Net income of 40,239,000 contributed positively to equity growth.
- New share issuances of 17,010,000 increased equity.
- Other comprehensive income decreased equity by 1,999,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs40.24 Million | +2.91% |
| Share Issuances | Rs17.01 Million | +1.23% |
| Other Comprehensive Income | Rs-2.00 Million | -0.14% |
| Other Changes | Rs1.82 Million | +0.13% |
| Total Change | Rs- | 4.30% |
Book Value vs Market Value Analysis
This analysis compares Aarey Drugs & Pharmaceuticals Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.85x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.51x to 1.85x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-03-31 | Rs13.99 | Rs91.08 | x |
| 2010-03-31 | Rs15.35 | Rs91.08 | x |
| 2011-03-31 | Rs36.51 | Rs91.08 | x |
| 2012-03-31 | Rs65.62 | Rs91.08 | x |
| 2013-03-31 | Rs19.91 | Rs91.08 | x |
| 2014-03-31 | Rs20.53 | Rs91.08 | x |
| 2015-03-31 | Rs21.06 | Rs91.08 | x |
| 2016-03-31 | Rs21.82 | Rs91.08 | x |
| 2017-03-31 | Rs27.85 | Rs91.08 | x |
| 2018-03-31 | Rs34.32 | Rs91.08 | x |
| 2019-03-31 | Rs37.01 | Rs91.08 | x |
| 2020-03-31 | Rs39.49 | Rs91.08 | x |
| 2021-03-31 | Rs42.28 | Rs91.08 | x |
| 2022-03-31 | Rs47.20 | Rs91.08 | x |
| 2023-03-31 | Rs46.25 | Rs91.08 | x |
| 2024-03-31 | Rs52.24 | Rs91.08 | x |
| 2025-03-31 | Rs49.36 | Rs91.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aarey Drugs & Pharmaceuticals Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.85%
- • Asset Turnover: 1.99x
- • Equity Multiplier: 1.72x
- Recent ROE (2.91%) is below the historical average (5.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 10.78% | 3.29% | 1.79x | 1.83x | Rs652.53K |
| 2010 | 8.80% | 1.74% | 1.78x | 2.84x | Rs-1.10 Million |
| 2011 | 3.61% | 1.17% | 1.59x | 1.95x | Rs-14.00 Million |
| 2012 | 0.87% | 0.22% | 1.50x | 2.65x | Rs-29.97 Million |
| 2013 | 1.97% | 0.38% | 1.61x | 3.20x | Rs-26.89 Million |
| 2014 | 3.04% | 0.53% | 1.87x | 3.10x | Rs-24.01 Million |
| 2015 | 3.07% | 0.51% | 1.86x | 3.25x | Rs-24.53 Million |
| 2016 | 3.51% | 0.52% | 1.97x | 3.41x | Rs-23.80 Million |
| 2017 | 11.68% | 1.49% | 2.76x | 2.84x | Rs8.46 Million |
| 2018 | 7.70% | 1.77% | 2.05x | 2.12x | Rs-18.47 Million |
| 2019 | 7.56% | 1.84% | 2.43x | 1.68x | Rs-21.14 Million |
| 2020 | 6.27% | 1.93% | 1.55x | 2.10x | Rs-34.41 Million |
| 2021 | 6.59% | 1.87% | 1.49x | 2.36x | Rs-33.72 Million |
| 2022 | 5.77% | 1.33% | 2.01x | 2.16x | Rs-48.09 Million |
| 2023 | 3.21% | 0.90% | 1.44x | 2.48x | Rs-79.70 Million |
| 2024 | 3.53% | 1.19% | 1.30x | 2.28x | Rs-85.94 Million |
| 2025 | 2.91% | 0.85% | 1.99x | 1.72x | Rs-98.24 Million |
Industry Comparison
This section compares Aarey Drugs & Pharmaceuticals Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $26,238,269,556
- Average return on equity (ROE) among peers: 9.06%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | Rs1.49 Billion | 10.78% | 0.98x | $27.93 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $6.52 Billion | 21.67% | 1.42x | $371.43 Million |
| Aarti Pharmalabs Limited (AARTIPHARM) | $19.90 Billion | 13.69% | 0.46x | $725.68 Million |
| Abbott India Limited (ABBOTINDIA) | $36.99 Billion | 32.48% | 0.40x | $5.85 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $1.16 Billion | 12.69% | 1.32x | $3.81 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $6.25 Billion | -40.39% | 3.91x | $906.19 Million |
| Alkem Laboratories Limited (ALKEM) | $88.47 Billion | 18.60% | 0.59x | $6.98 Billion |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $1.46 Billion | 16.82% | 0.29x | $178.52 Million |
| Alembic Pharmaceuticals Limited (APLLTD) | $51.90 Billion | 11.24% | 0.50x | $1.60 Billion |
| Aurobindo Pharma Limited (AUROPHARMA) | $23.50 Billion | -5.26% | 1.65x | $8.73 Billion |
About Aarey Drugs & Pharmaceuticals Limited
Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, intermediates, and specialty chemicals for various industrial applications in India. The company offers intermediates, including mono methyl urea, di methyl urea, ortho para nitro anisole, 2-bromomethyl-1,3-dioxolane, and uracil. It also provides active pharmaceutical ingredients, such as metformin HCl… Read more